A086040 Stock Overview
Engages in the safety evaluation of synthetic medicines, biomedicines, cell therapy products, gene therapy products, health functional foods, chemicals, and pesticides in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Biotoxtech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,045.00 |
| 52 Week High | ₩7,430.00 |
| 52 Week Low | ₩3,040.00 |
| Beta | 0.28 |
| 11 Month Change | -31.19% |
| 3 Month Change | -38.36% |
| 1 Year Change | -50.89% |
| 33 Year Change | -61.60% |
| 5 Year Change | -53.37% |
| Change since IPO | -60.56% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their Feet
Oct 21
Is Biotoxtech (KOSDAQ:086040) A Risky Investment?
May 06Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)
Mar 28Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?
Feb 20Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?
Jan 24
We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory Earnings
Dec 27Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?
Nov 30Shareholder Returns
| A086040 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -1.9% | -3.0% | 2.9% |
| 1Y | -50.9% | 33.7% | -2.8% |
Return vs Industry: A086040 underperformed the KR Life Sciences industry which returned 33.7% over the past year.
Return vs Market: A086040 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A086040 volatility | |
|---|---|
| A086040 Average Weekly Movement | 6.6% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A086040 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A086040's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 214 | Jong-Koo Kang | www.biotoxtech.com |
Biotoxtech Co., Ltd. engages in the safety evaluation of synthetic medicines, biomedicines, cell therapy products, gene therapy products, health functional foods, chemicals, and pesticides in South Korea. It is involved in testing and substance screening, clinical pathology and histopathology work, and consulting and government affairs related to non-clinical trials, as well as new drug development. The company’s safety evaluation research field includes general toxicity test, carcinogenicity studies, local toxicity studies, reproductive and developmental studies, genotoxicity test, immunotoxicity test, safety pharmacology test, aquatic ecotoxicology test, histopathology/clinical pathology, and animal testing method.
Biotoxtech Co., Ltd. Fundamentals Summary
| A086040 fundamental statistics | |
|---|---|
| Market cap | ₩48.50b |
| Earnings (TTM) | -₩4.94b |
| Revenue (TTM) | ₩34.47b |
1.4x
P/S Ratio-9.8x
P/E RatioIs A086040 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086040 income statement (TTM) | |
|---|---|
| Revenue | ₩34.47b |
| Cost of Revenue | ₩34.60b |
| Gross Profit | -₩127.70m |
| Other Expenses | ₩4.81b |
| Earnings | -₩4.94b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -310.31 |
| Gross Margin | -0.37% |
| Net Profit Margin | -14.34% |
| Debt/Equity Ratio | 136.2% |
How did A086040 perform over the long term?
See historical performance and comparison